Richter, Hetero Labs Partner on Generic of Ozempic

Hungarian pharmaceutical company Gedeon Richter announced the signing of a global collaboration agreement with Indian peer Hetero Labs on the joint development, registration and commercialization of a semaglutide injection, a generic of the anti-diabetic drug Ozempic, the Hungarian company has announced on thew website of the Budapest Stock Exchange.

The agreement combines the companies’ complementary strengths under a coordinated global framework, with clearly defined territorial responsibilities and a balanced cost- and profitsharing model. Operating through a joint governance structure, the partners ensure aligned decision-making and efficient execution.

Hetero has already made significant development investments, including technology setup and registration batch manufacturing. Regulatory filings are underway, with EU and US submissions planned for 2027. The collaboration leverages Hetero’s proven market reach within the United States and Emerging Markets, as well as Richter’s well-established commercial infrastructure across Europe and Central Asia, while maintaining optionality for future European manufacturing by Richter.

“This collaboration reflects the strong alignment, commitment, and shared pursuit of excellence between Hetero and Richter, forming a powerful partnership. It will enable us to deliver high‑quality, affordable therapies to patients living with diabetes and related cardiometabolic conditions worldwide,” according to Dr. Bence Kovács, Global Head of General Medicines at Richter.

“We are delighted to collaborate with Richter, as our strategic partner for Semaglutide Injection. This strategic Partnership brings together the deep local expertise of Hetero and Richter to broaden the global access to Semaglutide Injection therapy” Dr. Vamsi Krishna Bandi, Managing Director, Hetero Labs Ltd. pointed out.